Analysts Offer Insights on Healthcare Companies: Xilio Therapeutics (XLO) and Neurocrine (NBIX)
Promising Clinical Trials and Potential Therapies Propel Buy Rating for Xilio Therapeutics
Chardan Capital Sticks to Its Buy Rating for Xilio Therapeutics (XLO)
Chardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target
Chardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target
Morgan Stanley Adjusts Price Target on Xilio Therapeutics to $10 From $20, Maintains Overweight Rating
Xilio Therapeutics Analyst Ratings
Morgan Stanley Maintains Overweight on Xilio Therapeutics, Lowers Price Target to $10
Xilio Therapeutics Analyst Ratings
Chardan Capital Initiates Coverage On Xilio Therapeutics With Buy Rating, Announces Price Target of $7
Raymond James Adjusts Price Target on Xilio Therapeutics to $13 From $31, Maintains Outperform Rating
Xilio Therapeutics Analyst Ratings
Raymond James Maintains Outperform on Xilio Therapeutics, Lowers Price Target to $13
Xilio Therapeutics analyst ratings
Morgan Stanley Maintains Overweight on Xilio Therapeutics, Lowers Price Target to $20
Morgan Stanley Adjusts Price Target on Xilio Therapeutics to $20 From $32, Reiterates Overweight Rating
No Data